Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non‐small cell lung cancer
Pharmacological Research · 2023-10 · 196 · 106921
DOI: 10.1016/j.phrs.2023.106921 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Research, 2023-10. Verfasst von Wei Guo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Extracellular Vesicles, Immunotherapy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chinese Academy of Medical Sciences Initiative for Innovative Medicine, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Neoadjuvant immunotherapy has brought new hope for patients with non-small cell lung cancer (NSCLC). However, limited by the lack of clinically feasible markers, it is still difficult to select NSCLC patients who respond well and to predict patients' clinical outcomes before the treatment. Before the treatment, we isolated plasma extracellular vesicles (EVs) from three cohorts (discovery, training and validation) of 78 NSCLC patients treated with neoadjuvant immunotherapy. To identify differentially-expressed EV long RNAs (exLRs), we employed RNA-seq in the discovery cohort. And we subsequently used qRT-PCR to establish and validate the predictive signature in the other two cohorts. We have identified 8 candidate exLRs from 27 top-ranked exLRs differentially expressed between responders and non-responders, and tested their expression with qRT-PCR in the training cohort. We finally identified H3C2 (P = 0.029), MALAT1 (P = 0.043) and RPS3 (P = 0.0086) significantly expressed in responders for establishing the predictive signature. Integrated with PD-L1 expression, our signature performed well in predicting immunotherapeutic responses in the training (AUC=0.892) and validation cohorts (AUC=0.747). Furthermore, our signature was proven to be a predictor for favorable prognosis of patients treated with neoadjuvant immunotherapy, which demonstrates the feasibility of our signature in clinical practices (P = 0.048). Our results demonstrate that the exLR-based signature could accurately predict responses to neoadjuvant immunotherapy and prognosis in NSCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of Ch…
Förderung
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Guo, W., Zhou, B., Zhao, L., Huai, Q., Tan, F., Xue, Q., Lv, F., Gao, S., & He, J. (2023). Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non‐small cell lung cancer. Pharmacological Research, 196, 106921. https://doi.org/10.1016/j.phrs.2023.106921
Vancouver
Guo W, Zhou B, Zhao L, Huai Q, Tan F, Xue Q, et al. Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non‐small cell lung cancer. Pharmacological Research. 2023;196:106921. doi:10.1016/j.phrs.2023.106921
BibTeX
@article{Guo2023,
author = {Guo, Wei and Zhou, Bolun and Zhao, Liang and Huai, Qilin and Tan, Fengwei and Xue, Qi and Lv, Fang and Gao, Shugeng and He, Jie},
title = {Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non‐small cell lung cancer},
journal = {Pharmacological Research},
year = {2023},
volume = {196},
pages = {106921},
doi = {10.1016/j.phrs.2023.106921}
}
EUVIMED